(1R,5S,6s)-3-methyl-3-azabicyclo[3.1.0]hexan-6-amine | 1258290-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1R,5S,6s)-3-methyl-3-azabicyclo[3.1.0]hexan-6-amine
• CAS: 1258290-36-6
• 化学式: C₆H₁₂N₂
• 分子量: 112.175
• InChiKey: YSRSYYHGSQMAFV-FMCRUOTFSA-N

物化性质

• 沸点：
  140.6±8.0 °C(Predicted)
• 密度：
  1.057±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.49
• 重原子数：
  8.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.26
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  N-甲基马来酰亚胺 在 palladium on activated charcoal sodium tetrahydroborate 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 80.0 ℃ 、344.75 kPa 条件下， 反应 17.58h， 生成 (1R,5S,6s)-3-methyl-3-azabicyclo[3.1.0]hexan-6-amine
  参考文献：
  名称：

  HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF

  摘要：

  公式（IA）的化合物及其药用可接受的盐被描述。还描述了它们的制备过程、含有它们的药物组合物、它们作为药物的使用以及它们在治疗细菌感染中的用途。

  公开号：

  US20100317624A1

文献信息

• [EN] TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS<br/>[FR] INHIBITEURS TRICYCLIQUES DE GYRASE UTILISABLES COMME AGENTS ANTIBACTÉRIENS
  申请人：TRIUS THERAPEUTICS INC

  公开号：WO2014043272A1

  公开（公告）日：2014-03-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有化学式I结构的化合物及其药用盐、酯和前药，这些化合物可用作抗菌有效的三环酶抑制剂。此外，本文还披露了三环酶抑制剂化合物的种属。还考虑了相关的药用组合物、用途和制备这些化合物的方法。
• [EN] 5H-ISOTHIAZOLO[4,5-C]PYRIDINE-3,4-DIONE OR 5H-PYRAZOLO[4,3-C]PYRIDIN-3,4-DIONE AS ANTIBACTERIAL COMPOUNDS<br/>[FR] 5H-ISOTHIAZOLO[4,5-C]PYRIDINE-3,4-DIONE OU 5H-PYRAZOLO[4,3-C]PYRIDINE-3,4-DIONE EN TANT QUE COMPOSÉS ANTIBACTÉRIENS
  申请人：REDX PHARMA PLC

  公开号：WO2015114317A1

  公开（公告）日：2015-08-06

  This invention relates to antibacterial drug compounds of formula (I) containing a fused isothiazolinone or pyrazolone ring and related compounds. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial infections and in methods of treating bacterial infections. Many of the antibacterial drug compounds contain a isothiazolinone or pyrazolone ring fused to a pyridone ring. The compounds have broad spectrum antibacterial activity but are particularly effective against Gram negative strains. wherein X is selected from S, SO, SO2, O and NR4;

  这项发明涉及公式（I）中含有融合异噻唑酮或吡唑酮环及相关化合物的抗菌药物化合物。它还涉及抗菌药物化合物的制药配方。它还涉及衍生物在治疗细菌感染和治疗细菌感染方法中的用途。许多抗菌药物化合物含有融合到吡啶酮环的异噻唑酮或吡唑酮环。这些化合物具有广谱抗菌活性，但对革兰氏阴性菌株特别有效。其中X从S、SO、SO2、O和NR4中选择。
• [EN] BICYCLIC INHIBITORS OF PAD4<br/>[FR] INHIBITEURS BICYCLIQUES DE PAD4
  申请人：PADLOCK THERAPEUTICS INC

  公开号：WO2017100594A1

  公开（公告）日：2017-06-15

  The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

  本发明提供了用作PAD4抑制剂的化合物、其组合物以及治疗与PAD4相关疾病的方法。
• [EN] ANTIMICROBIAL COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ANTIMICROBIENS ET PROCÉDÉS
  申请人：CURZA GLOBAL LLC

  公开号：WO2021097061A1

  公开（公告）日：2021-05-20

  The application is directed to compounds that are active as antibacterial agents. The compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes for making the compounds.

  该应用程序涉及作为抗菌剂活性的化合物。这些化合物对革兰氏阳性和革兰氏阴性细菌具有活性，并可用于治疗由革兰氏阳性和革兰氏阴性细菌引起的感染。还公开了制备这些化合物的方法。
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：REDX PHARMA PLC

  公开号：WO2015155549A1

  公开（公告）日：2015-10-15

  This invention relates to antibacterial and anti-mycobacterial drug compounds of formula I. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial infections and to methods of treating bacterial infections. The invention is also directed to antibacterial drug compounds which are capable of treating bacterial infections which are currently hard to treat with existing drug compounds, e.g. those caused by resistant bacterial or mycobacterial strains.

  这项发明涉及公式I的抗菌和抗分枝杆菌药物化合物。它还涉及抗菌药物化合物的制药配方。它还涉及利用这些衍生物治疗细菌感染的用途，以及治疗细菌感染的方法。该发明还针对能够治疗目前难以用现有药物化合物治疗的细菌感染的抗菌药物化合物，例如由耐药细菌或分枝杆菌株引起的感染。